Online inquiry

IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7959MR)

This product GTTS-WQ7959MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL7R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002185.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3575
UniProt ID P16871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7959MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ455MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ5547MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ15493MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ1093MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ1669MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ6869MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ11700MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ2139MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW